Skip to main content
SpringerLink
Log in

Ocular Disease in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

  • Chapter
  • First Online:
Foundations of Corneal Disease

Abstract

Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are on a spectrum of a rare and potentially fatal immune-mediated mucocutaneous disease. As mortality rates decrease, more survivors are left with chronic complications including those of the ocular surface. SJS/TEN can result in severe, debilitating ocular surface disease that can lead to corneal blindness. Ophthalmic care from the time of admission onwards is crucial in mitigating the acute and chronic manifestations of SJS/TEN. This chapter discusses the ocular manifestations of disease in the acute and chronic phases, systemic and topical treatment, and the future of care in SJS/TEN.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AMT:

Amniotic membrane transplantation

BKP2:

Type 2 Boston keratoprosthesis

IVIG:

Intravenous immunoglobulin

LSCD:

Limbal stem cell deficiency

MMG:

Mucous membrane graft

MOOKP:

Modified osteo-odonto-keratoprosthesis

OSDI:

Ocular surface disease index

PED:

Persistent epithelial defects

PROSE:

Prosthetic replacement of the ocular surface ecosystem

SCORTEN:

SCORe of toxic epidermal necrolysis

SJS:

Stevens-Johnson syndrome

TEN:

Toxic epidermal necrolysis

References

  1. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126:43–7.

    Article  CAS  PubMed  Google Scholar 

  2. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome.An epidemiologic study from West Germany. Arch Dermatol. 1991;127:839–42.

    Article  CAS  PubMed  Google Scholar 

  3. Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, et al. Epidemiology of erythema exsudativummultiformemajus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49(7):769–73.

    Article  CAS  PubMed  Google Scholar 

  4. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J InvestigDermatol. 2016;136(7):1387–97.

    CAS  Google Scholar 

  5. Roujeau J, Kelly J, Naldi L, Rzany B, Stern R, Anderson T, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600–8.

    Article  CAS  PubMed  Google Scholar 

  6. Sharma V, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J DermatolVenereolLeprol. 2008;74(3):238–40.

    Google Scholar 

  7. Chantaphakul H, Sanon T, Klaewsongkram J. Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. ExpTher Med. 2015;10(2):519–24.

    Article  Google Scholar 

  8. Mockenhaupt V, Dunant N, Halevy B, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: results on drug risks based on the EuroSCAR-study. J InvestigDermatol. 2005;125(3):A76.

    Google Scholar 

  9. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35–44.

    Article  CAS  PubMed  Google Scholar 

  10. Assier H, Bastuji-Garin S, Revuz J, et al. Erythema multiforme with mucous membrane involvement and Stevens–Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131(5):539–43.

    Article  CAS  PubMed  Google Scholar 

  11. Dodiuk-Gad R, Chung W, Valeyrie-Allanore L, Shear N. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J ClinDermatol. 2015;16(6):475–93.

    Google Scholar 

  12. Haber J, Hopman W, Gomez M, Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil. 2005;26:33–41.

    Article  PubMed  Google Scholar 

  13. Magina S, Lisboa C, Leal V, et al. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology. 2003;207:33–6.

    Article  CAS  PubMed  Google Scholar 

  14. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am AcadDermatol. 2013;69:187.e1–18716. quiz 203–4.

    Article  CAS  Google Scholar 

  15. Kohanim S, Palioura S, Saeed HN, et al. Acute and chronic ophthalmic & involvement in Stevens – Johnson syndrome/toxic epidermal necrolysis – a comprehensive review and guide to therapy. II Ophthalmic disease. Ocul Surf. 2016;14:168–88.

    Article  PubMed  Google Scholar 

  16. Lopez-Garcia JS, Rivas Jara L, Garcia-Lozano CI, et al. Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis. Ophthalmology. 2011;118:265–71.

    Article  PubMed  Google Scholar 

  17. Gueudry J, Roujeau JC, Binaghi M, et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145:157–62.

    PubMed  Google Scholar 

  18. Morales ME, Purdue GF, Verity SM, et al. Ophthalmic manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN. Am J Ophthalmol. 2010;150:505–510.e1.

    Article  PubMed  Google Scholar 

  19. Chang YS, Huang FC, Tseng SH, et al. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007;26:123–9.

    Article  PubMed  Google Scholar 

  20. Chow L, Shih K, Chan J, Lai J, Ng A. Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study. BMC Ophthalmol. 2017;17(1):1–7.

    Article  CAS  Google Scholar 

  21. Saeed HN, Chodosh J. Ocular manifestations of Stevens–Johnson syndrome and their management. Curr Opin Ophthalmol. 2016;27(6):522–9.

    Article  PubMed  Google Scholar 

  22. Ang AY, Palmon FE, Holland EJ. Erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis-30. In: Ocular surface disease: cornea, conjunctiva and tear film; 2013. p. 231–41.

    Chapter  Google Scholar 

  23. Isawi H, Dhaliwal DK. Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use. J Cataract Refract Surg. 2007;33:1644–6.

    Article  PubMed  Google Scholar 

  24. Sachdev R, Bansal S, Sinha R, et al. Bilateral microbial keratitis in highly active antiretroviral therapy-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a case series. OculImmunolInflamm. 2011;19:343–5.

    Google Scholar 

  25. Alsuhaibani AH, Carter KD, Abramoff MD, Nerad JA. Utility of meibography in the evaluation of meibomian glands morphology in normal and diseased eyelids. Saudi J Ophthalmol. 2011;25:61–6.

    Article  PubMed  Google Scholar 

  26. Iyer G, Srinivasan B, Agarwal S, Kamala Muralidharan S, Arumugam S. Comprehensive approach to ocular consequences of Stevens Johnson syndrome – the aftermath of a systemic condition. Graefes Arch Clin Exp Ophthalmol. 2014;252(3):457–67.

    Article  PubMed  Google Scholar 

  27. Basu S, Shanbhag SS, Gokani A, Kedar R, Bahuguna C, Sangwan VS. Chronic ocular sequelae of Stevens-Johnson syndrome in children: long-term impact of appropriate therapy on natural history of disease. Am J Ophthalmol. 2018;189:17–28.

    Article  PubMed  Google Scholar 

  28. Catt H, Fish M, Ali. Ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Am J Ophthalmol. 2016;166:68–75.

    Article  PubMed  Google Scholar 

  29. Choi SH, Kim MK, Oh JY. Corneal limbal stem cell deficiency in children with stevens-johnson syndrome. Am J Ophthalmol. 2019;199:1–8. https://doi.org/10.1016/j.ajo.2018.10.016.

    Article  PubMed  Google Scholar 

  30. De Rojas M, Dart J, Saw V. The natural history of Stevens–Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol. 2007;91(8):1048–53.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Arstikaitis MJ. Ocular aftermath of Stevens-Johnson syndrome. Arch Ophthalmol. 1973;90:376–9.

    Article  CAS  PubMed  Google Scholar 

  32. Di Pascuale MA, Espana EM, Liu DT, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology. 2005;112:904–12.

    Article  PubMed  Google Scholar 

  33. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis.

    Google Scholar 

  34. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.

    Google Scholar 

  35. Heur M, Bach D, Theophanous C, Chiu GB. Prosthetic replacement of the ocular surface ecosystem scleral lenstherapy for patients with ocular symptoms of chronic Stevens-Johnson syndrome. Am J Ophthalmol. 2014;158(1):49–54.

    Article  PubMed  Google Scholar 

  36. Papakostas TD, Le HG CJ, Jacobs DS. Prosthetic replacement of the ocular surface ecosystem as treatment for ocular surface disease in patients with ahistory of Stevens–Johnson syndrome/toxic epidermal necrolysis. Ophthalmology. 2015;122(2):248–53.

    Article  PubMed  Google Scholar 

  37. Kaido M, Yamada M, Sotozono C, Kinoshita S, Shimazaki J, Tagawa Y, et al. The relation between visual performance and clinical ocular manifestations in Stevens-Johnson Syndrome. Am J Ophthalmol. 2012;154(3):499–511.e1.

    Article  PubMed  Google Scholar 

  38. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102(11):1669–76.

    Article  CAS  PubMed  Google Scholar 

  39. Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, et al. Predictive factors associated with acute ocular involvement in Stevens-Johnson Syndrome and toxic epidermal necrolysis. Am J Ophthalmol. 2015;160(2):228–237.e2.

    Article  PubMed  Google Scholar 

  40. Gregory D. New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 2016;123(8):1653–8.

    Article  PubMed  Google Scholar 

  41. Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007;62(5):527–31.

    Article  CAS  PubMed  Google Scholar 

  42. Sotozono C, Ang LP, Koizumi N, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology. 2007;114(7):1294–302.

    Article  PubMed  Google Scholar 

  43. Chow L, Ng A, Chow S, Choy B, Shih K, Wong I, et al. A cross-sectional comparative study on chronic ocular manifestations of Stevens–Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year case series. Int Ophthalmol. 2018;38(3):1155–60.

    Article  PubMed  Google Scholar 

  44. Foster CS, Fong LP, Azar D, et al. Episodic conjunctival inflammation after Stevens–Johnson syndrome. Ophthalmology. 1988;95:453–62.

    Article  CAS  PubMed  Google Scholar 

  45. Chang V, Chodosh J, Papaliodis G. Chronic ocular complications of Stevens–Johnson syndrome and toxic epidermal necrolysis: the role of systemic immunomodulatory therapy. Semin Ophthalmol. 2016;31(1–2):178–87.

    Article  CAS  PubMed  Google Scholar 

  46. Kim KH, Park SW, Kim MK, Wee WR. Effect of age and early intervention with a systemic steroid, intravenous immunoglobulin or amniotic membrane transplantation on the ocular outcomes of patients with Stevens-Johnson syndrome. Korean J Ophthalmol. 2013;27:331–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Araki Y, Sotozono C, Inatomi T, et al. Successful treatment of Stevens- Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol. 2009;147:1004–11–11 e1.

    Article  CAS  Google Scholar 

  48. Kim DH, Yoon KC, Seo KY, et al. The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome. Ophthalmology. 2015;122:254–64.

    Article  PubMed  Google Scholar 

  49. Le HG, Saeed HN, Mantagos I, Mitchell C, Goverman J, Chodosh J. Burn unit care of Stevens Johnson syndrome/toxic epidermal necrolysis: a survey. Burns. 2016;42(4):830–5.

    Article  PubMed  Google Scholar 

  50. Sotozono C, Ueta M, Koizumi N, et al. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology. 2009;116:685–90.

    Article  PubMed  Google Scholar 

  51. Tomlins PJ, Parulekar MV, Rauz S. “Triple-TEN” in the treatment of acute ocular complications from toxic epidermal necrolysis. Cornea. 2013;32:365–9.

    Article  PubMed  Google Scholar 

  52. Kim JC, Tseng SC. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. Cornea. 1995;14:473–84.

    Article  CAS  PubMed  Google Scholar 

  53. Kim JC, Tseng SC. The effects on inhibition of corneal neovascularization after human amniotic membrane transplantation in severely damaged rabbit corneas. Korean J Ophthalmol. 1995;9:32–46.

    Article  CAS  PubMed  Google Scholar 

  54. Mamede AC, Carvalho MJ, Abrantes AM, et al. Amniotic membrane: from structure and functions to clinical applications. Cell Tissue Res. 2012;349:447–58.

    Article  CAS  PubMed  Google Scholar 

  55. Zhou S, Chen J, Xu L, et al. Fresh amniotic membrane transplantation for conjunctival surface reconstruction. Yan KeXueBao. 1999;15:169–73.

    CAS  Google Scholar 

  56. Honavar SG, Bansal AK, Sangwan VS, Rao GN. Amniotic membrane transplantation for ocular surface reconstruction in Stevens-Johnson syndrome. Ophthalmology. 2000;107:975–9.

    Article  CAS  PubMed  Google Scholar 

  57. John T, Foulks GN, John ME, et al. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmology. 2002;109:351–60.

    Article  PubMed  Google Scholar 

  58. Gregory DG. Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases. Ophthalmology. 2011;118:908–14.

    Article  PubMed  Google Scholar 

  59. Hsu M, Jayaram A, Verner R, et al. Indications and outcomes of amniotic membrane transplantation in the management of acute stevens-johnson syndrome and toxic epidermal necrolysis: a case-controlstudy. Cornea. 2012;31:1394–402.

    Article  PubMed  Google Scholar 

  60. Sotozono C, Inatomi T, Nakamura T, et al. Visual improvement after cultivated oral mucosal epithelial transplantation. Ophthalmology. 2013;120:193–200.

    Article  PubMed  Google Scholar 

  61. Shammas MC, Lai EC, Sarkar JS, et al. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol. 2010;149:203–213.e2.

    Article  CAS  PubMed  Google Scholar 

  62. Sharma T, Kaur P, Khanna A, Vajpayee. Adjuvant role of amniotic membrane transplantation in acute ocular Stevens–Johnson syndrome: a randomized control trial: arandomized control trial. Ophthalmology. 2016;123(3):484–91.

    Article  PubMed  Google Scholar 

  63. Cai M, Zhang J, Guan L, Zhao M. Novel implantable composite biomaterial by fibrin glue and amniotic membrane for ocular surface reconstruction. J Mater Sci Mater Med. 2015;26(3):1–8.

    Article  CAS  Google Scholar 

  64. Agrawal A, Pratap V. Amniotic membrane transplantation (AMT) without the use of sutures/fibrin glue. Nepalese J Ophthalmol: A Biannual Peer-reviewed Academic Journal of the Nepal Ophthalmic Society: NEPJOPH. 2015;7(14):173–7.

    Article  Google Scholar 

  65. Kucukerdonmez C, Karalezli A, Akova Y, Borazan M. Amniotic membrane transplantation using fibrin glue in pterygium surgery: a comparative randomised clinical trial. Eye. 2010;24(4):558–66.

    Article  CAS  PubMed  Google Scholar 

  66. Kheirkhah C, Blanco L, Hayashida C, Tseng. Amniotic membrane transplantation with fibrin glue for conjunctivochalasis. Am J Ophthalmol. 2007;144(2):311–3.

    Article  CAS  PubMed  Google Scholar 

  67. Shanbhag SS, Chodosh J, Saeed HN. Sutureless amniotic membrane transplantation with cyanoacrylate glue for acute Stevens-Johnson syndrome/toxic epidermal necrolysis. Ocul Surf. 2019;14(2). [Epub ahead of print].

    Google Scholar 

  68. Marinho DR, Burmann TG, Kwitko S. Labial salivary gland transplantation for severe dry eye due to chemical burns and Stevens-Johnson syndrome. OphthalPlastReconstrSurg. 2010;26:182–4.

    Google Scholar 

  69. Leibovitch I, Hoyama E, Limawararut V, et al. Novel technique to control hypersecretion from a transplanted autologous submandibular salivary gland for keratoconjunctivitissicca. Cornea. 2006;25:1251–3.

    Article  PubMed  Google Scholar 

  70. Sotozono C, Ueta M, Yokoi N. Severe dry eye with combined mechanisms is involved in the ocular sequelae of SJS/TEN at the chronic stage. Investig Ophthalmol Vis Sci. 2018;59(14):DES80–6.

    Article  CAS  Google Scholar 

  71. Iyer G, Pillai VS, Srinivasan B, et al. Mucous membrane grafting for lid margin keratinization in Stevens-Johnson syndrome: results. Cornea. 2010;29:146–51.

    Article  PubMed  Google Scholar 

  72. Fu Y, Liu J, Tseng SC. Oral mucosal graft to correct lid margin pathologic features in cicatricial ocular surface diseases. Am J Ophthalmol. 2011;152:600–608.e1.

    Article  PubMed  Google Scholar 

  73. Sant’Anna AE, Hazarbassanov RM, de Freitas D, Gomes JA. Minor salivary glands and labial mucous membrane graft in the treatment of severe symblepharon and dry eye in patients with Stevens-Johnson syndrome. Br J Ophthalmol. 2012;96:234–9.

    Article  Google Scholar 

  74. Haefliger IO, Vysniauskiene I, Pimentel AR, et al. Free autologous buccal mucosal graft transplantation to treat ocular complications after toxic epidermal necrolysis: case report. KlinMonatsblAugenheilkd. 2004;221:395–7.

    CAS  Google Scholar 

  75. Gurumurthy S, Iyer G, Srinivasan B, Agarwal S, Angayarkanni N. Ocular surface cytokine profile in chronic Stevens-Johnson syndrome and its response to mucous membrane grafting for lid margin keratinisation. Br J Ophthalmol. 2017;102(2):169–76.

    Article  PubMed  Google Scholar 

  76. Tougeron-Brousseau B, Delcampe A, Gueudry J, et al. Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol. 2009;148:852–859.e2.

    Article  PubMed  Google Scholar 

  77. Siqueira AC, Santos MS, Farias CC, et al. Scleral contact lens for ocular rehabilitation in patients with Stevens-Johnson syndrome. Arq Bras Oftalmol. 2010;73:428–32. Portuguese.

    Article  PubMed  Google Scholar 

  78. Parra AS, Roth BM, Nguyen TM, Wang L, Pflugfelder SC, Al-Mohtaseb Z. Assessment of the Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) scleral lens on visual acuity for corneal irregularity and ocular surface disease. Ocul Surf. 2018;16(2):254–8.

    Article  PubMed  Google Scholar 

  79. Wang Y, Rao R, Jacobs DS, Saeed HN. Prosthetic replacement of the ocular surface ecosystem treatment for ocular surface disease in pediatric patients with Stevens-Johnson syndrome. Am J Ophthalmol. 2019;201:1–8.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Iyer G, Srinivasan B, Agarwal S, et al. Treatment modalities and clinical & outcomes in ocular sequelae of Stevens –Johnson syndrome over 25 years – a paradigm shift. Cornea. 2016;35:46–50.

    Article  PubMed  Google Scholar 

  81. Sayegh RR, Ang LP, Foster CS, Dohlman CH. The Boston keratopros- thesis in Stevens-Johnson syndrome. Am J Ophthalmol. 2008;145:438–44.

    Article  PubMed  Google Scholar 

  82. Gomaa A, Comyn O, Liu C. Keratoprostheses in clinical practice – a review. Clin Exp Ophthalmol. 2010;38:211–24.

    Article  Google Scholar 

  83. Durand ML, Dohlman CH. Successfulpreventionofbacterialendophthalmitis in eyes with the Boston keratoprosthesis. Cornea. 2009;28:896–901.

    Article  PubMed  Google Scholar 

  84. Rootman DB, Kim MJ, Aldave AJ, et al. Ocular surface, fornix, and eyelid rehabilitation in Boston type I keratoprosthesis patients with mucous membrane disease. OphthalPlastReconstrSurg. 2015;31:43–9.

    Google Scholar 

  85. De La Paz MF, De Toledo JA, Charoenrook V, et al. Impact of clinical factors on the long-term functional and anatomic outcomes of osteo-odonto-keratoprosthesis and tibial bone keratoprosthesis. Am J Ophthalmol. 2011;151:829–839.e1.

    Article  Google Scholar 

  86. Basu S, Pillai V, Sangwan VS. Mucosal complications of modified osteo-odontokeratoprosthesis in chronic Stevens-Johnson Syndrome. Am J Ophthalmol. 2013;156(5):867–873.e2.

    Article  PubMed  Google Scholar 

  87. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: amarkerforStevens-Johnsonsyndrome. Nature. 2004;428:486.

    Article  CAS  PubMed  Google Scholar 

  88. Ueta M. Genetic predisposition to Stevens-Johnson syndrome with severe ocular surface complications. Cornea. 2015;34:S158–65.

    Article  PubMed  Google Scholar 

  89. Ueta M, Tokunaga K, Sotozono C, Sawai H, Tamiya G, Inatomi T, et al. HLA-A∗0206 with TLR3 polymorphisms exerts more than additive effects in Stevens-Johnson syndrome with severe ocular surface complications (gene-geneinteraction between HLA-A∗0206 and TLR3). 2012;7(8):E43650.

    Google Scholar 

  90. Lee HS, Ueta MK, Kim MY, Seo KC, Sotozono C, Kinoshita S, Yoon K. Analysis of Ocular Manifestation and Genetic association of allopurinol-induced Stevens–Johnson Syndrome and toxic epidermal necrolysis in South Korea. Cornea. 2016;35(2):199–204.

    Article  PubMed  Google Scholar 

  91. Ueta MC, Kinoshita SK, Sawai HY, Tokunaga K, Shingaki R, Kawai Y, et al. Genome-wide association study using the ethnicity-specific Japonica array: identification of new susceptibility loci for cold medicine-related Stevens-Johnson syndrome with severe ocular complications. J Hum Genet. 2017;62(4):485–9.

    Article  CAS  PubMed  Google Scholar 

  92. Wakamatsu T, Ueta M, Tokunaga K. Human leukocyte antigen class I genes associated with Stevens-Johnson syndrome and severe ocular complications following use of cold medicine in a Brazilian population. JAMA Ophthalmol. 2017;135(4):355–60.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Kannabiran C, Ueta M, Sangwan V, Rathi V, Basu S, Tokunaga K, Kinoshita S. Association of Human Leukocyte Antigen Class 1 genes with Stevens Johnson Syndrome with severe ocular complications in an Indian population. Sci Rep (Nature Publisher Group). 2017;7(1):1–4.

    CAS  Google Scholar 

  94. Jongkhajornpong P, Lekhanont K, Pisuchpen P, Chantaren P, Puangsricharern V, Prabhasawat P, et al. Association between HLA-B∗44:03-HLA-C∗07:01 haplotype and cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Thailand. Br J Ophthalmol. 2018;102(9):1303–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adult and Pediatric Cornea and Refractive Surgery, Massachusetts Eye and Ear, Boston Children’s Hospital, Department of Ophthalmology, Boston, MA, USA

    Hajirah N. Saeed

  2. Tufts University Medical Center, Massachusetts Eye and Ear, Department of Ophthalmology, Boston, MA, USA

    Ramy Rashad

Authors
  1. Hajirah N. Saeed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ramy Rashad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hajirah N. Saeed .

Editor information

Editors and Affiliations

  1. Louis Block Professor Chair, Department of Ophthalmology and Visual Science, The University of Chicago Medicine & Biological Sciences, Chicago, IL, USA

    Kathryn Colby

  2. Claes H. Dohlman Professor of Ophthalmology, Harvard Medical School, Cornea & Refractive Surgery, Massachusetts Eye & Ear, Boston, MA, USA

    Reza Dana

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Saeed, H.N., Rashad, R. (2020). Ocular Disease in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. In: Colby, K., Dana, R. (eds) Foundations of Corneal Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-25335-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25335-6_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25334-9

  • Online ISBN: 978-3-030-25335-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation